Background-IL-33 through its receptor ST2 protects the heart from myocardial infarct and hypertrophy in animal models but, paradoxically, increases autoimmune disease. In this study, we examined the effect of IL-33 or ST2 administration on autoimmune heart disease. Methods and Results-We used pressure-volume relationships and isoproterenol challenge to assess the effect of recombinant (r) IL-33 or rST2 (eg, soluble ST2) administration on the development of autoimmune coxsackievirus B3 myocarditis and dilated cardiomyopathy in male BALB/c mice. The rIL-33 treatment significantly increased acute perimyocarditis (Pϭ0.006) and eosinophilia (Pϭ1.3ϫ10 Ϫ5 ), impaired cardiac function (maximum ventricular power, Pϭ0.0002), and increased ventricular dilation (end-diastolic volume, Pϭ0.01). The rST2 treatment prevented eosinophilia and improved heart function compared with rIL-33 treatment (ejection fraction, Pϭ0.009). Neither treatment altered viral replication. The rIL-33 treatment increased IL-4, IL-33, IL-1␤, and IL-6 levels in the heart during acute myocarditis. To determine whether IL-33 altered cardiac function on its own, we administered rIL-33 to undiseased mice and found that rIL-33 induced eosinophilic pericarditis and adversely affected heart function. We used cytokine knockout mice to determine that this effect was due to IL-33-mediated signaling but not to IL-1␤ or IL-6. Conclusions-We show for the first time to our knowledge that IL-33 induces eosinophilic pericarditis, whereas soluble ST2 prevents eosinophilia and improves systolic function, and that IL-33 independently adversely affects heart function through the IL-33 receptor. (Circ Heart Fail. 2012;5:366-375.)
M yocarditis, or inflammation of the myocardium, leads to Ϸ46% of the dilated cardiomyopathy (DCM) cases in the United States, whereas DCM is the most common form of cardiomyopathy responsible for heart failure. [1] [2] [3] Coxsackievirus B3 (CVB3) is a major cause of myocarditis and DCM in humans, 2 and infection of mice with heart-passaged CVB3 (containing infectious virus and cardiac tissue) induces autoimmune myocarditis leading to DCM. 4 Only mice that respond to infection with a T helper (Th) 2 immune response progress from acute myocarditis to chronic myocarditis and DCM. 4 -6 In patients with heart failure, elevated serum levels of proinflammatory cytokines, such as tumor necrosis factor-␣ (TNF-␣) and IL-6, independently predict decreased heart function and poor survival. 7 IL-1␤ and TNF-␣ worsen heart disease during myocarditis by increasing inflammation and inducing myocyte hypertrophy, contractile dysfunction, and extracellular matrix remodeling. 6, 8, 9 Clinical Perspective on p 375 IL-33 is a cytokine in the IL-1␤ family that promotes a Th2 response. 10 IL-1 receptor-like 1 protein, most often abbreviated ST2, exists in 2 major isoforms: a membrane-bound form (ST2L) that is the receptor for IL-33 and a truncated soluble form (sST2) generated by alternative splicing that binds IL-33 and is believed to act as a decoy receptor. Recently, elevated serum and synovial fluid levels of IL-33 were associated with rheumatoid arthritis in patients, and administration of recombinant (r) IL-33 increased collagen or antibody-induced arthritis in mice. [11] [12] [13] Paradoxically, IL-33 has been shown to be cardioprotective in murine models of myocardial infarct and hypertrophy, where rIL-33 administration improves heart function and diminishes inflammation and fibrosis. 14, 15 In this study, we were interested in determining the effect of rIL-33 administration on an autoimmune model of CVB3 myocarditis that progresses to DCM in susceptible strains of mice. We found that rIL-33 impaired cardiac function during myocarditis and in undiseased mice. Although IL-1␤ and IL-6 were increased in the heart by rIL-33 treatment and are cytokines capable of causing cardiac dysfunction on their own, we showed that the negative effects of IL-33 on cardiac function occur through the IL-33 receptor and are not due to IL-1␤ or IL-6.
Methods

Experimental Model
BALB/cJ, C57BL/6J, B6.129SF2/J, type I IL-1R, IL-6, and IL1RAcP-deficient male mice (Jackson Laboratory) were maintained under pathogen-free conditions in the animal facility at the Johns Hopkins School of Medicine, and approval was obtained from the Johns Hopkins University Animal Care and Use Committee for all procedures. Mice were inoculated intraperitoneally with heartpassaged CVB3 on day 0, and hearts were examined on day 10 postinfection during acute myocarditis or day 35 postinfection during DCM. 4 rIL-33 (1 g/0.1 mL), rST2 (5 g/0.1 mL), or sterile PBS were injected intraperitoneally on days 1, 3, 5, 7, and 9 in undiseased or CVB3-infected mice. Hearts were fixed in 10% buffered formalin and stained with hematoxylin eosin to assess inflammation, as previously described. 6
Cardiac Function
Cardiac function was assessed by a 1.2F pressure-volume catheter (Scisense Inc) placed in the left ventricle through the apex in open-chest mice anesthetized with 3% isoflurane, as previously described. 16 -18 To assess ␤-adrenergic sensitivity, an isoproterenol dose-response protocol was adapted from previous protocols. 19, 20 
Plaque Assay and Cytokine Measurements
Individual cardiac supernatants or sera were used in ELISA to measure cytokines or in plaque assays to determine the level of infectious virus, as previously described. 4, 6 
Flow Cytometry
Hearts were digested with 600 /mL collagenase II (Worthington) plus 60 /mL DNAse I (Sigma) according to the manufacturer's instructions for the GentleMACS (Miltenyi) isolation of cardiac cells. [21] [22] [23] Immune cells were stained with fluorochrome-conjugated antibodies against CD45, CD3, CD4, CD19, FcR1␣, CD117, CD11b, F4/80, Ly6G, or SiglecF (BD Pharmingen/eBiosciences). 
Statistical Analysis
The Mann-Whitney rank sum test was used to evaluate 2 groups (PϽ0.05). Comparisons involving 3 groups were analyzed using the Kruskal-Wallis test. When 3 groups were significant (PϽ0.05), then pairwise comparisons were made using Mann-Whitney rank tests with a Bonferroni correction (PϽ0.013). Repeated-measures data (ie, isoproterenol treatments) were evaluated using generalized estimating equations and linear mixed-effects models, with dose as a covariate. An omnibus test for group differences was used at the first stage (PϽ0.05), and if significant, pairwise comparisons were assessed (PϽ0.013).
Results
IL-33 Increases Eosinophilic Perimyocarditis Without Affecting Virus Levels
We recently reported that IL-33 mRNA levels are significantly elevated in the heart during acute and chronic CVB3 myocarditis. 24 To examine the effects of rIL-33 administration in an autoimmune model of viral-induced heart disease, we treated BALB/c mice with rIL-33, rST2 (to block IL-33 released during myocarditis), 25 or PBS administered intraperitoneally every other day from days 1 to 9 postinfection and examined myocarditis at day 10 postinfection. We found that rIL-33 treatment significantly increased CVB3 myocarditis (Pϭ0.006) ( Figure 1A and 1C) and pericarditis ( Figure  1D ) compared with PBS controls, whereas rST2 did not (Pϭ0. 19) . Neither rIL-33 nor rST2 treatment significantly altered viral replication compared with PBS controls (PBS versus rIL-33, Pϭ0.16; PBS versus rST2, Pϭ0.66) ( Figure  1B) . The rIL-33 treatment significantly increased the number of eosinophils in the heart by histology ( Figure 1E ) and fluorescence-activated cell sorting analysis (absolute numbers, Pϭ0.001; percentages, Pϭ1.3ϫ10 Ϫ5 ) ( Figure 1F and 1G). No other major cell populations, such as lymphocytes, monocytes, macrophages, neutrophils, or mast cells, were increased by rIL-33 treatment by fluorescence-activated cell sorting analysis (data not shown). The rST2-treated mice did not develop pericardial or myocardial eosinophilia ( Figure 1D ).
rIL-33 Exacerbates Cardiac Dysfunction During CVB3 Myocarditis and DCM, But rST2 Improves Cardiac Function
To determine the effect of IL-33 or ST2 administration on cardiac function, we gave male BALB/c mice rIL-33, rST2, or PBS intraperitoneally every other day from days 1 to 9 postinfection and examined cardiac function at day 10 or 35 postinfection using pressure-volume relationships. We found that rIL-33 significantly decreased cardiac function, whereas rST2 improved function (Figure 2 , Tables 1 and 2 ). In this myocarditis model, susceptible strains of mice, like BALB/c, recover from acute myocarditis but develop DCM by day 35 postinfection. 4, 6 At day 35 postinfection, mice that received rIL-33 from days 1 to 9 postinfection developed worse dilation and reduced ejection fraction (Pϭ0.01) compared with PBS controls (Figure 2 , Table 2 ). The rST2 treatment improved cardiac function during chronic myocarditis in mice that received rST2 from days 1 to 9 postinfection ( Figure 2 , Table 2 ). See the online-only Data Supplement for a more-detailed description of cardiac function.
rIL-33 Induces Acute Cardiac Dysfunction and Pericarditis in Undiseased Mice
Administration of certain cytokines, like TNF-␣ or IL-1␤, is capable of causing acute cardiac dysfunction in normal mice. 9, 26 To assess whether rIL-33 induced cardiac dysfunc- tion in the absence of myocarditis, uninfected BALB/c mice were injected intraperitoneally with PBS, rIL-33, or rST2 every other day for a total of 5 injections, and cardiac function was assessed the day after the final treatment (the equivalent of day 10) using pressure-volume relationships or at day 35 by echocardiography. The rIL-33 treatment impaired cardiac function in the absence of myocarditis compared with PBS controls at day 10 ( Table 3 ) but not at day 35 Data are presented as median (interquartile range) for 8 to 10 mice per group. Male BALB/c mice received CVB3 at day 0 and either PBS, rIL-33, or rST2 intraperitoneally every other day, and data were collected at day 10 postinfection. r indicates recombinant; CVB3, coxsackievirus B3; HR, heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure; dP/dT max, peak rate of pressure rise; dP/dT min, peak rate of pressure decline; EF, ejection fraction; ESV, end-systolic volume; EDV, end-diastolic volume; SV, stroke volume; CO, cardiac output; SW, stroke work; PRSW, preload recruitable stroke work; PMX, maximum ventricular power; Ees, left ventricular end-systolic elastance; Ea/Ees, arterial elastance normalized to Ees; V 0 , x intercept of the ESP-volume relationship; , time constant of diastolic relaxation.
*PBS vs rIL-33. †PBS vs rST2. ‡rIL-33 vs rST2. Data are presented as median (interquartile range) for 8 to 10 mice per group. Male BALB/c mice received CVB3 at day 0 and either PBS, rIL-33, or rST2 intraperitoneally every other day from days 1 to 9 postinfection, and data were collected at day 35 postinfection. r indicates recombinant; CVB3, coxsackievirus B3; HR, heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure; dP/dT max, peak rate of pressure rise; dP/dT min, peak rate of pressure decline; EF, ejection fraction; ESV, end-systolic volume; EDV, end-diastolic volume; SV, stroke volume; CO, cardiac output; SW, stroke work; PRSW, preload recruitable stroke work; PMX, maximum ventricular power; Ees, left ventricular systolic elastance; Ea/Ees, arterial elastance normalized to Ees; V 0 , x intercept of the ESP-volume relationship; , time constant of diastolic relaxation.
*PBS vs rIL-33. †PBS vs rST2. ‡rIL-33 vs rST2.
(online-only Data Supplement Table I ). In contrast, rST2 treatment from days 1 to 9 had no significant effect on heart function compared with PBS controls at day 10 ( Table 3) . See the online-only Data Supplement for a more-detailed description of cardiac function in undiseased mice. The rIL-33 treatment induced pericarditis in undiseased mice (onlineonly Data Supplement Figure I ) that was similar in appearance to that observed during acute CVB3 myocarditis ( Figure  1D ). Eosinophils were abundant in the pericardial infiltrate of rIL-33 (online-only Data Supplement Figure IB ) but absent in rST2-treated mice (online-only Data Supplement Figure IC ).
rIL-33 Induces ␤-Adrenergic Insensitivity in Diseased and Undiseased Mice
␤-adrenergic insensitivity is a hallmark feature of heart failure. 27 Isoproterenol is a sympathomimetic agonist of ␤-receptors in the heart that is used to test adrenergic responsiveness in vivo. 28 Certain cytokines, including TNF-␣, IL-1␤, and IL-6, are able to inhibit myocyte function by interfering with calcium handling and by reducing the response to ␤-receptor stimulation. 26 Because administration of rIL-33 impaired systolic and diastolic function at day 10 postinfection (Table 1 ) and in undiseased mice (Table 3) , we tested the ability of rIL-33 to affect ␤-adrenergic responsiveness to isoproterenol. We found that rIL-33 treatment inhibited the characteristic increases in heart rate (PϽ0.0001), peak rate of pressure rise (Pϭ0.0001), cardiac output (Pϭ0.001), and maximum ventricular power (Pϭ0.001) in response to isoproterenol for mice with acute myocarditis and for undiseased mice (Figure 3 , online-only Data Supplement Table II ). The rST2 treatment did not significantly alter the response to isoproterenol for any of these parameters in diseased or undiseased mice. Neither rIL-33 nor rST2 affected ␤-adrenergic responsiveness to isoproterenol during the chronic phase of CVB3 myocarditis at day 35 postinfection (online-only Data Supplement Figure II , online-only Data Supplement Table II ).
rIL-33 Increases Cardiac IL-33, IL-4, IL-1␤, IL-6, and Serum sST2 and Alters Remodeling During Acute CVB3 Myocarditis
IL-33 has been demonstrated to promote Th2 responses. 12, 25, 29 For this reason, we examined the effect of rIL-33 or rST2 treatment on Th2-associated cytokines in the heart (eg, IL-4, IL-33, ST2) or sera (sST2) during acute CVB3 myocarditis by ELISA. IL-33 also promotes Th1-type proinflammatory responses, 30, 31 and so, we also examined proinflammatory/profibrotic cytokines (eg, interferon-␥ [IFN-␥], TNF-␣, IL-1␤, IL-6). sST2 is a serum biomarker that predicts progression to heart failure in patients. 24, 32 We found that rIL-33 treatment increased IL-33 (Pϭ0.01), IL-4 (Pϭ0.002), IL-1␤ (Pϭ0.0009), and IL-6 (Pϭ0.003) in the heart compared with PBS controls during acute myocarditis ( Figure 4A ) but had no effect on TNF-␣ (Pϭ0.76) ( Figure 4A ), IFN-␥ (Pϭ0.10), or sST2 (Pϭ0.41) in the heart (data not shown). The rIL-33 and rST2 treatments significantly increased serum levels of sST2 during acute myocarditis compared with PBS controls (Pϭ0.0001 and Pϭ0.0004, respectively) ( Figure 4A ). Importantly, rST2 treatment significantly decreased cardiac IL-33 compared with PBS con- Data are presented as median (interquartile range) for 8 to 10 mice per group. Male BALB/c mice received either PBS, rIL-33, or rST2 intraperitoneally every other day, and data collected 10 d later. r indicates recombinant; HR, heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure; dP/dT max, peak rate of pressure rise; dP/dT min, peak rate of pressure decline; EF, ejection fraction; ESV, end-systolic volume; EDV, end-diastolic volume; SV, stroke volume; CO, cardiac output; SW, stroke work; PRSW, preload recruitable stroke work; PMX, maximum ventricular power; Ees, left ventricular end-systolic elastance; Ea/Ees, arterial elastance normalized to Ees; V 0 , x intercept of the ESP-volume relationship; , time constant of diastolic relaxation.
trols (Pϭ0.001) ( Figure 4A ), indicating that rST2 treatment partially decreases cardiac IL-33 levels during acute myocarditis. The rST2 treatment had no effect on cardiac levels of IL-4 (Pϭ0.06), TNF-␣ (Pϭ0.10), IL-6 (Pϭ0.17) ( Figure  4A ), or sST2 (Pϭ0.65) and on IFN-␥ level (Pϭ0.20) (data not shown) compared with PBS controls during myocarditis. The rIL-33 treatment also significantly altered matrix metalloproteinase levels in the heart compared with PBS by real-time polymerase chain reaction (online-only Data Supplement).
rIL-33 Increases Cardiac IL-1␤ and IL-6 in Undiseased Mice
Because rIL-33 treatment increased cardiac IL-1␤ and IL-6 levels at day 10 postinfection ( Figure 4A) , we asked whether rIL-33 treatment of undiseased mice would also increase these cytokine levels in the heart. To test this, we administered PBS, rIL-33, or rST2 every other day as previously described and examined cytokines after the 5th treatment (equivalent to day 10) by ELISA. We found that rIL-33 significantly increased cardiac IL-6 levels (Pϭ0.01) that were prevented by rST2 treatment (Pϭ0.004) in undiseased mice compared with PBS controls but had no significant effect on TNF-␣ levels (Kruskal-Wallis Pϭ0.18, Mann-Whitney rank test Pϭ0.08) or IL-1␤ (Kruskal-Wallis Pϭ0.13, Mann-Whitney rank test Pϭ0.04) ( Figure 4B) . A comparison of cytokines in undiseased mice versus mice with acute CVB3 myocarditis revealed that rIL-33 treatment specifically increased cardiac IL-1␤ levels (Pϭ0.006) (rIL-33 group), whereas TNF-␣ (Pϭ0.002) and IL-6 (Pϭ0.008) levels were increased with disease (PBS group) (online-only Data Supplement Figure III ).
rIL-33 Treatment Directly Decreases Heart Function
Because rIL-33 treatment induced cardiac dysfunction and ␤-adrenergic insensitivity in diseased and undiseased mice at day 10, we wanted to determine whether IL-33 could be independently responsible for these effects. 9, 26 However, because rIL-33 treatment increased IL-1␤ and IL-6 levels in the heart (Figure 4 , online-only Data Supplement Figure III) , it was possible that IL-33 worked indirectly to alter heart function through these cytokines. To test this possibility, we treated undiseased male IL-1R-, IL-6-, or IL-1RAcP-(receptor required for IL-1R-and IL-33R-mediated signaling) 10 deficient mice with PBS or rIL-33, using the same protocol as before, and examined heart function by pressure-volume relationships. We found that rIL-33 treatment significantly Figure 3. A and B, The rIL-33 treatment induces ␤-adrenergic insensitivity during coxsackievirus B3 myocarditis at day 10 postinfection and in undiseased mice at day 10, respectively. BALB/c mice received either coxsackievirus B3 at day 0 and PBS, rIL-33, or rST2 every other day from days 1 to 9 postinfection or PBS, rIL-33, or rST2 every other day from days 1 to 9 but no virus. Data are presented as meanϮSEM of 10 to 12 mice per group. *Compares rIL-33 to PBStreated mice (PϽ0.013). There were no significant differences in rST2-treated mice compared with PBS controls. †PϽ0.05 using generalized estimating equations and linear mixed-effects models for 3 groups. bpm indicates beats/ min; CO, cardiac output; dP/dT Max, peak rate of pressure rise; HR, heart rate; PMX, maximum ventricular power; r, recombinant.
decreased most cardiac functional parameters compared with PBS-treated IL-1R-or IL-6-deficient mice ( Figure 5A and 5B), indicating that IL-1␤ and IL-6 were not responsible for the effect of rIL-33. Cardiac dysfunction following rIL-33 treatment was not significantly different from PBS controls for any parameter examined in IL-1RAcP-deficient mice ( Figure 5C ), demonstrating that IL-33R is required for the cardiac dysfunction observed in rIL-33-treated mice.
Because IL-1␤ has been shown to be critical for myocarditis, 8, 33 we examined whether rIL-33 increased CVB3 myocarditis indirectly through IL-1␤ by treating IL-1R-deficient mice with rIL-33 from days 1 to 9 postinfection. We found that although rIL-33 significantly increased myocarditis compared with PBS controls, there was no significant difference in myocarditis between wild-type and IL-1R-deficient mice in response to rIL-33 (online-only Data Supplement Figure  IV) . Thus, rIL-33 does not increase acute CVB3 myocarditis through IL-1␤.
Discussion
In this study, we demonstrate that rIL-33 administration induces eosinophilic pericardial inflammation, resulting in dilation during acute CVB3 myocarditis and in undiseased hearts. To our knowledge, we are the first to report that IL-33 induces eosinophilic myocarditis and pericarditis. Previously, we showed that IFN-␥-deficient mice develop a Th2-type immune response that leads to eosinophilic pericarditis, dilation, and heart failure. 6, 34 IL- 33 had not yet been discovered and, thus, was not examined in those studies. Recently, we showed that TIR-domain-containing adapter-inducing IFN-␤-deficient mice have elevated IL-33 levels in the heart that is associated with dilation, fibrosis, and heart failure. 18 Eosinophilic cardiovascular diseases, such as Churg-Strauss syndrome, Kounis syndrome, hypereosinophilic syndrome, eosinophilic myocarditis, and giant cell myocarditis, are associated with poor heart function and dilation similar to the present findings. 2, 35, 36 Recently, rIL-33 administration has been found to promote lung eosinophilia in an animal model of asthma. 29, 37 The induction of eosinophilic pericarditis by rIL-33 in our model provides a possible explanation for the divergent results we obtained compared with myocardial infarct and aortic constriction animal models as reported by Sanada et al 14 and Seki et al. 15 Eosinophils release cationic proteins, such as major basic protein, metalloproteinases, and cytokines, that contribute to cardiac remodeling and dilation. 35, 36 We report here that rIL-33 treatment increased the profibrotic cytokines IL-4 and IL-1␤ as well as altered the metalloproteinase levels in the heart during myocarditis that contribute to cardiac remodeling. Although the precise reasons the results differ from those of other investigators remain unclear, a possible explanation is that we used a different dose and murine rather than rat rIL-33 in these studies. 14, 15 Additionally, we observe sex differences in IL-33 and ST2 levels and function during myocarditis, and we used male mice in these experiments, but the sex used in the other studies was not described. Interestingly, hypereosinophilic syndrome occurs more frequently in men than in women (9:1). 36 Importantly, the effects of rIL-33 administration on chronic CVB3 myocarditis and DCM were detected at day 35 postinfection, 25 days after rIL-33 treatment finished (recombinant administered from days 1-9 postinfection), indicating that early effects of IL-33 (ie, innate, during acute myocarditis) were responsible for increasing DCM. Others have reported effects of cytokines on heart function that continued up to 10 days after cytokine administration finishes. 38 However, the effect of rIL-33 on dilation was only short term in undiseased hearts. Additionally, we demonstrated in the present study that IL-33 induces cardiac dysfunction independently from IL-1␤ or IL-6 but requires the IL-33R. This observation is novel. The similarity of IL-33/ST2L signaling to IL-1␤/IL-1R signaling suggests a possible mechanism for the observed effect. IL-33R, ST2L, and IL-1R share the common IL-1RAcP component, which activates MyD88 and NFB. 10, 39, 40 Administration of IL-1␤ to rodents induces systolic and diastolic dysfunction as well as ␤-adrenergic insensitivity. 9, 41, 42 The present observation that rIL-33 administration independently affects cardiac dilation, however, is an effect that has been observed for TNF-␣ but not for IL-1␤, 41, 42 suggesting that important differences exist between IL-1␤/IL-1R and IL-33/ST2L signaling pathways in the heart.
To our knowledge, we report for the first time that rST2 effectively protects the heart from cardiac dysfunction during acute and chronic CVB3 myocarditis and DCM. Administration of rST2 (eg, sST2) in animal models of myocardial infarct and pressure overload is believed to function as a decoy receptor to counteract IL-33 released during heart damage. 10 In this study, rST2 treatment significantly reduced cardiac IL-33 levels in the heart during acute CVB3 myocarditis compared with PBS controls, but the reduction was small perhaps because the R&D ELISA kit does not distinguish between IL-33 that is bound or unbound to ST2. Thus, some of the IL-33 that we detected in the heart could be inactivated, accounting for the strongly protective effect of rST2 treatment. That heart function was conserved essentially to normal undiseased levels by rST2 treatment indicates the importance of sST2 in protecting the heart from inflammatory heart disease and its role in preventing eosinophilia. Additionally, rST2 administration from days 1 to 9 postinfection effectively prevented progression to DCM, causing susceptible BALB/c mice to resemble resistant mouse strains such as C57BL/6. 4 In summary, the present study demonstrates that IL-33 induces eosinophilic pericarditis and increases CVB3 perimyocarditis and DCM, whereas ST2 is protective. Although this is a promising pathway to investigate novel therapeutic interventions for cardiovascular disease and heart failure in particular, therapies targeting the IL-33/ST2 pathway will need to take into account the ability of IL-33 to induce cardiac eosinophilia and pericarditis. 
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